P-132 Blood plasma mRNA sequencing for monitoring therapy response in esophageal adenocarcinoma patients

Abstract

The incidence of esophageal adenocarcinoma (EAC), a histological subtype of esophageal cancer, has rapidly increased in the Western world in the last decades. It is an aggressive cancer with an unacceptably low five-year survival rate (10–25%), despite improved treatment strategies. The tumor is often detected in a late stage due to a lack of symptoms or they are not recognized. This results in a complex treatment and tough recovery. Neoadjuvant chemoradiotherapy is ineffective for many patients.